Not sure about the initial waves. Low volume, hard to count. Asset could double still, easily. One of the potential future market leaders, yet, trading at a discount to its peers.
Hello Everyone, With President-elect Joe Biden set to take office in the new year, marijuana stocks may gain some positive momentum. My prior analysis back in June of this year predicted a consolidation followed by a breakout (see below). It now seems price has entered a more bullish territory. Now may be a time to consider additional long positions. On...
So far nothing impulsive, but wave 5 could still extend here.
Many pot stocks have bottomed. CRLBF is supposed to come with killer earnings, but Trump blocking stimulus may see us dump before pump.
Earnings beat and a solid confirmation of successful integration of Origin House. Will we see a break out today? After all, these are not the kind of earnings to sell, if you ask me.
Good Afternoon Traders, Due to the recent earnings report released by CRLBF and possible formation of a new Support, the recent upward trend may continue to a new Resistance. The Cannabis Industry has been releasing positive Quarterly Reports during the ongoing COVID crisis. This may prove Cannabis to be a more inelastic good than previously thought. On the...
Evening Traders, Today’s Analysis – CRLBF – showing signs of a confirmed trend change, holding structural support will establish another higher low. Points to consider, - S/R Flip at structural level - Structural resistance (Immediate target) - RSI Cooling off - Stochastic in upper regions - 21 Moving Average (Visual guide) - Increasing bull...
A company with excellent moat, solid fundamentals and rapid growth. Earnings coming on Monday. Direction will largely depend on the numbers. Trend line broken, now packing energy to attack weekly resistance. Above $6.50, CRLBF will be free to pursue new highs...
They expect their new shelf prospectus and reverse split to be completed on May 11. Based on last week's market cap, we would be looking at 35% dilution, but after yesterday's sell off, it is getting closer to 50%. I had a buy box for a bounce play, but for the time being, I will be avoiding ACB like the plague. ACB and CGC, they once were kings of a promised...
This company is still so young, it is hard to find levels of confluence and targets. I figured to just draw FIB chart from $0 to the top, to see how that would look, and it seems to provide more than just a few levels. I don't want to go out my way to analyse this asset before I'm certain that a bottom is in. Currently still trading below MA20, and I think it...
Comparing the stock performances of familiar US MSO's to the SSO Liberty Health Sciences so far in 2020. LHS still holding a 7% gain with Curaleaf @ 3% even after the recent week of sector selling. Can't say the same for the majority of their peers though.
Good underlying strength, support at $6 held yesterday, fundamentally strong. Packing a lot of energy and could be headed for a break out at the first bullish news... This is a largely ignored MSO, and they are definitely worth a closer look.
Uptrend with M continuation pattern. Indicators show underlying strength. Merger with Origin House completed. This could get catapulted back to former highs, or at least the $8-9 range.
I'll be receiving my 0.71 Cresco Labs shares for every Origin House share I owned. I bought them at a discount, so I am very pleased that this merger is closed now. What is ahead for Cresco? Completion saw a small sell off, which I think could be expected. Not actually sure. Perhaps it was just the broader market playing it down. I think there is a bull thesis...
Hello Traders! Today’s chart update will be on CRLBF – CRESCO LABS INC, potential trend reversal if local resistance is broken. Price is building up near resistance, is a break imminent? Points to consider, - Trend bearish, attempting a higher low - Support provided by the EMA’s - Local resistance being tested - Stochastics projected upwards - RSI respecting...
Slight bearish convergence on the Stoch, and also RSI indicating a possible hourly pullback. Earnings are guided, so the revenue figures are not very likely to drive the price upward. We're looking for profitability. ACB predicted Q4 profitability. The press release issueing earnings guidance only mentioned that they are moving closer to achieve positive EBITDA....